KRAS and neoplasm: Its influence on the TIME includes two aspects: one promotes the activation of TIL-B, resulting in its anti-tumor activity; the second suppresses the expression of tumor suppressors (RB and p21) and oncogenic proteins (Kras, Akt, ERK, STAT3, CDK6, and CDK4) (135).